Brain Cancer Trial Uses Patient's Own Tumor Cells to Train Immune System
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
20 articles
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Small study explores cerebrospinal fluid exosomes to better diagnose breast cancer spread to brain and spinal cord.
New diagnostic chip analyzes blood exosomes to detect early lung spread of bone cancer, potentially improving treatment outcomes.
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.